Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2016 Apr 6;77(5):1039–1052. doi: 10.1007/s00280-016-3018-6

Figure 6.

Figure 6

Sorafenib and SG efflux via Abcc2. Black circles and curve: WT; Red circles and curve: Abcc2 KO. The shaded region shows the variability in the disposition when SG Abcc2 activity is decreased from baseline value to 0 and another undefined sinusoidal membrane efflux transporter’s activity is increased 2 fold.